Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Matthew Raymond Smith, M.D., PH.D.

TitleProfessor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Cox 640, Hematology/Oncology
100 Blossom Street
Boston MA 02114
Phone617/726-8515

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Smith MR. Androgen deprivation therapy and acute kidney injury. JAMA. 2013 Dec 4; 310(21):2313.
    View in: PubMed
  2. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9.
    View in: PubMed
  3. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6.
    View in: PubMed
  4. Smith MR. Cancer: ADT and acute kidney injury-causal or casual relationship? Nat Rev Endocrinol. 2013 Oct; 9(10):568-70.
    View in: PubMed
  5. Taksler GB, Cutler DM, Giovannucci E, Smith MR, Keating NL. Ultraviolet index and racial differences in prostate cancer incidence and mortality. Cancer. 2013 Sep 1; 119(17):3195-203.
    View in: PubMed
  6. Lee RJ, Saylor PJ, Dror Michaelson M, Michael Rothenberg S, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 1; 19(11):3088-94.
    View in: PubMed
  7. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-44.
    View in: PubMed
  8. Lee RJ, Smith MR. Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer. Cancer J. 2013 Jan; 19(1):90-8.
    View in: PubMed
  9. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S45-50.
    View in: PubMed
  10. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
    View in: PubMed
  11. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20.
    View in: PubMed
  12. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9.
    View in: PubMed
  13. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003.
    View in: PubMed
  14. Morgans AK, Smith MR, O'Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013 Feb 15; 119(4):863-70.
    View in: PubMed
  15. Keating NL, O'Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012 Oct 3; 104(19):1518-23.
    View in: PubMed
  16. Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2012 Nov; 53(11):1670-5.
    View in: PubMed
  17. Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):533-46.
    View in: PubMed
  18. D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med. 2012 Aug 16; 367(7):e11.
    View in: PubMed
  19. Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2012; 6:287-303.
    View in: PubMed
  20. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10; 30(26):3271-6.
    View in: PubMed
  21. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 1; 18(13):3677-85.
    View in: PubMed
  22. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52.
    View in: PubMed
  23. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013 Jul; 64(1):159-66.
    View in: PubMed
  24. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
  25. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28.
    View in: PubMed
  26. Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012 Mar; 187(3):889-93.
    View in: PubMed
  27. Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec; 26(12):2827-33.
    View in: PubMed
  28. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 7; 379(9810):39-46.
    View in: PubMed
  29. Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011 Dec; 186(6):2239-44.
    View in: PubMed
  30. Morgans AK, Smith MR. RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. J Osteoporos. 2011; 2011:941310.
    View in: PubMed
  31. Smith MR, Klotz L, van der Meulen E, Colli E, Tankó LB. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011 Nov; 186(5):1835-42.
    View in: PubMed
  32. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14.
    View in: PubMed
  33. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6.
    View in: PubMed
  34. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
    View in: PubMed
  35. Smith MR, Zietman AL, Finkelstein JS, Wu CL. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. N Engl J Med. 2011 May 26; 364(21):2044-51.
    View in: PubMed
  36. Smith MR. Effective treatment for early-stage prostate cancer--possible, necessary, or both? N Engl J Med. 2011 May 5; 364(18):1770-2.
    View in: PubMed
  37. Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer. 2011 Jun; 11(3):177-83.
    View in: PubMed
  38. Saylor PJ, Keating NL, Freedland SJ, Smith MR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61.
    View in: PubMed
  39. Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol. 2012 Jul-Aug; 30(4):369-78.
    View in: PubMed
  40. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 1; 8(1):29-36.
    View in: PubMed
  41. Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011 Jan; 27(1):55-62.
    View in: PubMed
  42. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011 May 15; 117(10):2077-85.
    View in: PubMed
  43. Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010 Dec; 184(6):2313-9.
    View in: PubMed
  44. Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8.
    View in: PubMed
  45. Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int. 2011 May; 107(10):1582-6.
    View in: PubMed
  46. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010 Oct; 184(4):1316-21.
    View in: PubMed
  47. Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res. 2010 Aug 15; 16(16):4084-93.
    View in: PubMed
  48. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6.
    View in: PubMed
  49. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5.
    View in: PubMed
  50. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95.
    View in: PubMed
  51. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20.
    View in: PubMed
  52. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23.
    View in: PubMed
  53. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22.
    View in: PubMed
  54. Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2.
    View in: PubMed
  55. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8.
    View in: PubMed
  56. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501.
    View in: PubMed
  57. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
    View in: PubMed
  58. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40.
    View in: PubMed
  59. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200.
    View in: PubMed
  60. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23.
    View in: PubMed
  61. Smith MR, Kantoff PW. Changes in PSA kinetics after DNA vaccine therapy-not so fast! J Clin Oncol. 2010 Feb 1; 28(4):e58; author reply e59.
    View in: PubMed
  62. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 6; 102(1):39-46.
    View in: PubMed
  63. Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec; 182(6):2670-5.
    View in: PubMed
  64. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94.
    View in: PubMed
  65. Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31.
    View in: PubMed
  66. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009 Oct; 7 Suppl 7:S1-29; quiz S30.
    View in: PubMed
  67. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20; 361(8):745-55.
    View in: PubMed
  68. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009; 9:272.
    View in: PubMed
  69. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009 Jun; 7 Suppl 3:S1-32; quiz S33-5.
    View in: PubMed
  70. Temel JS, Greer JA, Goldberg S, Vogel PD, Sullivan M, Pirl WF, Lynch TJ, Christiani DC, Smith MR. A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 May; 4(5):595-601.
    View in: PubMed
  71. Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol. 2009 May; 7(5 Suppl 11):1-30; quiz 31.
    View in: PubMed
  72. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8.
    View in: PubMed
  73. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 1; 27(1):92-9.
    View in: PubMed
  74. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95.
    View in: PubMed
  75. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009 Jan; 55(1):62-75.
    View in: PubMed
  76. Smith MR. Osteoporosis in men with prostate cancer: now for the fracture data. J Clin Oncol. 2008 Sep 20; 26(27):4371-2.
    View in: PubMed
  77. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008 Sep 10; 26(26):4333-9.
    View in: PubMed
  78. Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol. 2008 Jul-Aug; 26(4):420-5.
    View in: PubMed
  79. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39.
    View in: PubMed
  80. Smith MR. Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past? J Clin Oncol. 2008 Jun 20; 26(18):2932-3.
    View in: PubMed
  81. Smith MR, O'Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun; 101(11):1335-6.
    View in: PubMed
  82. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213.
    View in: PubMed
  83. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15; 112(10):2188-94.
    View in: PubMed
  84. Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008 May; 9(3):197-202.
    View in: PubMed
  85. Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008 Apr 10; 26(11):1824-9.
    View in: PubMed
  86. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36.
    View in: PubMed
  87. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008 Feb; 71(2):318-22.
    View in: PubMed
  88. Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology. 2008 Feb; 17(2):148-53.
    View in: PubMed
  89. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008 Oct; 54(4):816-23.
    View in: PubMed
  90. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83.
    View in: PubMed
  91. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9.
    View in: PubMed
  92. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
  93. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007 Dec 15; 110(12):2691-9.
    View in: PubMed
  94. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008 Jan; 179(1):152-5.
    View in: PubMed
  95. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007 Sep; 12(9):1035-43.
    View in: PubMed
  96. Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007 Aug; 70(2):315-9.
    View in: PubMed
  97. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007 Jun; 14(3):247-54.
    View in: PubMed
  98. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42.
    View in: PubMed
  99. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53.
    View in: PubMed
  100. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007 Jan 1; 13(1):241-5.
    View in: PubMed
  101. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6315s-6319s.
    View in: PubMed
  102. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6209s-6212s.
    View in: PubMed
  103. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20; 24(27):4448-56.
    View in: PubMed
  104. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 1; 107(3):530-5.
    View in: PubMed
  105. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8.
    View in: PubMed
  106. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 1):3361-7.
    View in: PubMed
  107. Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar; 15(3):293-305.
    View in: PubMed
  108. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr; 91(4):1305-8.
    View in: PubMed
  109. Smith MR. Markers of bone metabolism in prostate cancer. Cancer Treat Rev. 2006; 32 Suppl 1:23-6.
    View in: PubMed
  110. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006 Jan; 175(1):136-9; discussion 139.
    View in: PubMed
  111. Smith MR. Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol. 2005 Dec; 2(12):608-15; quiz 628.
    View in: PubMed
  112. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005 Nov 10; 23(32):8219-24.
    View in: PubMed
  113. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 1; 23(31):7897-903.
    View in: PubMed
  114. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005 Oct 15; 104(8):1633-7.
    View in: PubMed
  115. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005; 31 Suppl 3:19-25.
    View in: PubMed
  116. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 1; 23(13):2918-25.
    View in: PubMed
  117. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology. 2005 May; 65(5 Suppl):9-16; discussion 17.
    View in: PubMed
  118. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 1; 11(1):284-9.
    View in: PubMed
  119. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5.
    View in: PubMed
  120. Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S52-6; discussion S56-7.
    View in: PubMed
  121. Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004 Oct 15; 22(20):4233-4.
    View in: PubMed
  122. Smith MR. Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):367-75.
    View in: PubMed
  123. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 1; 101(7):1569-74.
    View in: PubMed
  124. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7.
    View in: PubMed
  125. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12.
    View in: PubMed
  126. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Aug; 89(8):3841-6.
    View in: PubMed
  127. Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004 Aug 1; 101(3):541-9.
    View in: PubMed
  128. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 1; 22(13):2546-53.
    View in: PubMed
  129. Smith MR. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology (Williston Park). 2004 May; 18(5 Suppl 3):21-5.
    View in: PubMed
  130. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2705-8.
    View in: PubMed
  131. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004 Apr; 63(4):742-5.
    View in: PubMed
  132. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 Mar 1; 100(5):892-9.
    View in: PubMed
  133. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S55-7; discussion S57-8.
    View in: PubMed
  134. Michaelson MD, Smith MR, Talcott JA. Prostate cancer (metastatic). Clin Evid. 2003 Dec; (10):1012-22.
    View in: PubMed
  135. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5.
    View in: PubMed
  136. Smith MR. Antitumor activity of bisphosphonates. Clin Cancer Res. 2003 Nov 15; 9(15):5433-4.
    View in: PubMed
  137. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 1; 21(23):4277-84.
    View in: PubMed
  138. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104.
    View in: PubMed
  139. Smith MR. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):18-21.
    View in: PubMed
  140. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 Jun; 169(6):2008-12.
    View in: PubMed
  141. Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 2003 Jun; 29(3):211-8.
    View in: PubMed
  142. Michaelson MD, Smith MR. The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5(3):245-9.
    View in: PubMed
  143. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003 Feb 1; 97(3 Suppl):789-95.
    View in: PubMed
  144. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 2003 Jan; 61(1):127-31.
    View in: PubMed
  145. Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2003; 21:547-64.
    View in: PubMed
  146. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003; 20(3):175-83.
    View in: PubMed
  147. Michaelson MD, Talcott JA, Smith MR. Prostate cancer: metastatic. Clin Evid. 2002 Dec; (8):881-90.
    View in: PubMed
  148. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002 Nov-Dec; 11(6):518-23.
    View in: PubMed
  149. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer. 2002 Nov 1; 95(9):1864-8.
    View in: PubMed
  150. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6.
    View in: PubMed
  151. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):79-85; discussion 86.
    View in: PubMed
  152. Smith MR, Fuchs V, Anderson EJ, Fallon MA, Manola J. Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer. Nutrition. 2002 Jul-Aug; 18(7-8):574-7.
    View in: PubMed
  153. Smith MR, Kantoff PW. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs. 2002 May; 20(2):195-200.
    View in: PubMed
  154. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002 Feb; 87(2):599-603.
    View in: PubMed
  155. Smith MR. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev. 2002; 21(2):159-66.
    View in: PubMed
  156. Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2002; 20:471-91.
    View in: PubMed
  157. Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest. 2002; 20(2):186-91.
    View in: PubMed
  158. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27; 345(13):948-55.
    View in: PubMed
  159. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001 Jun 15; 91(12):2238-45.
    View in: PubMed
  160. Smith MR. Complementary and alternative therapies for advanced prostate cancer. Hematol Oncol Clin North Am. 2001 Jun; 15(3):559-71.
    View in: PubMed
  161. Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff PW. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer. 2000 Oct 15; 89(8):1824-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Smith's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_